• sense clinically
  • think mechanistically
  • act interdisciplinarily
  • treat innovatively

Prof. Dr. rer. nat. Thomas Blankenstein

Molecular Immunology and Gene Therapy
Director of the Institute for Immunology
Charité - Universitätsmedizin Berlin
Max-Delbrück Center for Molecular Medicine (MDC)
Robert-Rössle-Str. 10
13092 Berlin


University Education

  • 1979-1983 Study of Biology, Universität Göttingen and Universität Köln
  • 1983-1987 Ph.D. thesis ate the Institute of Genetics, Universität Köln
  • 1991 Habilitation in Immunology, FU Berlin

Professional Experience (selection)

  • 1994- Research group leaser at the MDC
  • 1996-2000 Professor for "Molekulare Immunologie und Gentherapie", Faculty of BIology, FU Berlin

Research Fields

  • i) Main field: Cancer immunology
  • ii) Other fields: Cancer research, immunology

Most important Awards, Grants or Scientific Achievements

  • 1991 German Cancer Award
  • 2008-2010 DKH Grant
  • 2005- Member of the European Society for Cancer Immunology and Immunotherapy

Selected References

  • Li, L.P., Lampert, J.C., Chen, X., Leitao, C., Popovic, J., Müller, W., Blankenstein, T. (2010). Transgenic mice with a diverse human T cell antigen receptor repertoire. Nature Med 9, 1029.
  • Willimsky, G., Czeh, M., Loddenkemper, C., Gellermann, J., Schmidt, K., Wust, P., Stein, H., and Blankenstein, T. (2008). Immunogenicity of premalignant lesions is the primary cause of general cytoxic T lymphocyte unresponsiveness. J Exp Med 205, 1687.
  • Willimsky, G., and Blankenstein, T. (2005). Sporadic immunogenic tumors avoid destruction by inducing T cell tolerance. Nature 437, 141.